The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.
Likely to be Marginal ? Not so according to some claims . -March 10 2021 -Vir Biotechnology and GSK claim a monoclonal VIR 7831 which targets a "highly conserved epitope" on SARS-CoV-2 Shared with SARS-CoV-1 given IV to patients at high risk of hospital admission -291 in treatment arm 292 placebo led to an 85 % reduction in hospitalisation or death . -Called the COMET-ICE Trial . -Independent Data Monitoring Committee(IDMC ) said to have stopped trial because of profound efficacy . -Hopefully a second chance for those not vaccinated because of hesitancy or lack of reach .
I will stick to my guns on this one. These things are totally unproven. a new monoclonal Ab LY-CoV555 was just reported in NEJM to be useless in hospitalized patients. Other reports have shown monoclonal antibodies may be harmful for hospitalized patients. The cocktail product claims in a press release to reduce admissions from 3% to 1%. The information is not peer-reviewed but this would seem to be a marginal effect.
What you do matters.